论文部分内容阅读
作者对二丙酸氯地米松(Beclomethasone dipropionate,BDP)气溶胶的临床疗效和停服皮质激素后的肾上腺功能,在32例严重依赖激素的慢性哮喘患者中进行了研究。32例中,男17例,女15例。年龄25～65岁,平均50岁。其中有30例病史在6～21年以上,有12例口服糖皮质激素已达6～20年。患者均收入院,BDP治疗前常规作实验室、胸部X线及各项肺功能检查。在肌注Cosyntropin(为一种合成的促肾上腺皮质激素——译者注)0.25毫克之前以及注射后30分钟,测定血浆基础皮质醇水平,检查肾上腺功能。具备以下两条标准即为Cosyntropin试验阳性:(1)血浆皮质醇总的增长值应达7微克/100毫升以上;(2)血浆皮质醇的绝对值达到18微克/100毫升以上。肺功能每月复查一次,而肾上腺功能
The authors investigated the clinical efficacy of Beclomethasone dipropionate (BDP) aerosol and the adrenal function after stopping corticosteroids in 32 patients with severe asthma-dependent chronic asthma. 32 cases, 17 males and 15 females. Age 25 to 65 years old, average 50 years old. Among them, 30 cases have a history of more than 6 to 21 years, and 12 cases of oral glucocorticoid have reached 6 to 20 years. Patients were admitted to hospital, BDP conventional treatment for laboratory, chest X-ray and pulmonary function tests. Plasma basal cortisol levels were measured before adventitial Cosyntropin (a synthetic adrenocorticotrophic hormone) 0.25 mg and 30 min postinjection to examine adrenal function. Cosyntropin test is positive with the following two criteria: (1) The total increase in plasma cortisol should be above 7 μg / 100 ml; (2) The absolute value of plasma cortisol is above 18 μg / 100 ml. Pulmonary function once a month review, and adrenal function